Dropping the transcription factor from the four so-called Yamanaka factors reduces the efficiency of inducing the production of stem cells, but the resulting cells are of greater quality.

Many researchers see the move to relax the rules as a welcome change, yet some are worried the revisions don’t take public concerns enough into consideration.

Uncertainties about the cells’ risk profiles and the potential for hyping unproven therapies mean scientists and the media must tread carefully.

Changes in gene expression also hint at how the brains of people with ASD develop differently from those of other people.

Since their discovery in 2006, induced pluripotent stem cells have been poised to reprogram regenerative medicine. Twelve years on, here’s how far they’ve come.

This is the first time researchers have tested the use of the reprogrammed stem cells in the human brain.

Without knowing the cells’ mechanism of action, researchers question the best way to administer them to patients.

The $340 million, 30,000-square-foot center will produce cells for therapeutic applications.

Researchers use the technique to turn on Oct4 or Sox2 in mouse embryonic fibroblasts and convert them into pluripotent cells. 

The scientist was a member of a stem cell research team led by Nobel laureate Shinya Yamanaka. 

Michael Christman oversaw the organization’s well-known biobank and pioneered a personalized medicine initiative.

Combining gene editing and stem-cell induction improves efficiency of functional genetic analyses.

Simultaneous exposure to reprogramming and gene-editing plasmids efficiently produces edited pluripotent colonies.

Activating genes for reprogramming factors for a short time transforms large numbers of differentiated cells into multipotent forms that could be useful for cell-based therapies.

Using human induced pluripotent stem cells, scientists grew podocytes, cells that attach to the kidney's glomeruli and help filter blood.  

Researchers describe hundreds of induced pluripotent stem cell lines from healthy individuals. 

Two studies report methods to mimic human fetal brain development using neurons derived from human induced pluripotent stem cells that form 3-D, brain-like structures. 

Japanese health officials approve human experiments to treat macular degeneration with a cell therapy derived from induced pluripotent stem cells.

Removing a specific miRNA from stem cells may induce the expression of endogenous retroviruses that enable the cells to form extra-embryonic lineages.